Amgen (AMGN) : Investors lapped up stocks on upticks to the tune of $123.34 million in the Fridays trading session. The trading value on downticks was comparatively at $69.06 million and the uptick to downtick ratio of 1.79 indicates continuous buying by the bulls. The net money flow into the stock was $54.29 million. Upticks saw transactions worth $55.85 clearly indicating buying by large investors. The total money flow for block trades stood at $55.85 million, which is a positive for the stock in the long-term. Amgen (AMGN) fell $0.36 during the day at $169.77, a drop of -0.21% over the previous days close. However, for the week, the stock is -1.28%, compared to the previous week.
The company Insiders own 0.2% of Amgen shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -29.46% . Institutional Investors own 79.47% of Amgen shares. During last six month period, the net percent change held by insiders has seen a change of -25.63%.
In a related news,The officer (VP, Finance and CAO) of Amgen Inc, Such Annette Louise sold 3,000 shares at $174.59 on August 2, 2016. The Insider selling transaction had a total value worth of $523,770. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Amgen (NASDAQ:AMGN): stock was range-bound between the intraday low of $168.91 and the intraday high of $171.05 after having opened at $170.55 on Fridays session. The stock finally closed in the red at $170.55, a loss of -0.21%. The stock remained in the red for the whole trading day. The total traded volume was 2,083,804 shares. The stock failed to cross $171.05 in Fridays trading. The stocks closing price on Thursday was $170.13.
Amgen (AMGN) : During the past 4 weeks, traders have been relatively bearish on Amgen (AMGN), hence the stock is down -2.11% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -1.77% relative to the S&P 500. The 4-week change in the price of the stock is -2.24% and the stock has fallen -1.28% in the past 1 week.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Companys sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising, as well as through the Internet. Outside the United States, the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Companys products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim), Enbrel (etanercept), XGEVA/Prolia (denosumab), ESAs (erythropoiesis-stimulating agents), Sensipar/Mimpara (cinacalcet), Kyprolis and Evolocumab, among others.